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Abstract
Neuroblastoma (NB) is the most frequently observed among extracranial pediatric solid tumors. It displays an extreme
clinical heterogeneity, in particular for the presentation at diagnosis and response to treatment, often depending on cancer
cell differentiation/stemness. The frequent presence of elevated hematic and urinary levels of catecholamines in patients
affected by NB suggests that the dissection of adrenergic system is crucial for a better understanding of this cancer. β3-
adrenoreceptor (β3-AR) is the last identified member of adrenergic receptors, involved in different tumor conditions, such as
melanoma. Multiple studies have shown that the dysregulation of the bioactive lipid sphingosine 1-phosphate (S1P)
metabolism and signaling is involved in many pathological diseases including cancer. However, whether S1P is crucial for
NB progression and aggressiveness is still under investigation. Here we provide experimental evidence that β3-AR is
expressed in NB, both human specimens and cell lines, where it is critically involved in the activation of proliferation and the
regulation between stemness/differentiation, via its functional cross-talk with sphingosine kinase 2 (SK2)/S1P receptor 2
(S1P2) axis. The specific antagonism of β3-AR by SR59230A inhibits NB growth and tumor progression, by switching from
stemness to cell differentiation both in vivo and in vitro through the specific blockade of SK2/S1P2 signaling.
Introduction
Neuroblastoma (NB) is the most common extracranial solid
tumor occurring in childhood. NB arises from a sym-
pathoadrenal lineage progenitor of the neural crest during
development. It is a heterogeneous malignancy with prog-
nosis ranging from good outcome in low-risk disease to
poor survival in high-risk, depending on tumor biology and
clinical presentation at diagnosis. Molecular, genetic, and
biological features define the different clinical behaviors,
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varying from complete spontaneous differentiation and
regression to metastatic dissemination [1, 2]. A combination
of these features is currently used to stratify patients into
three groups, low-, intermediate and high-risk, according to
the International Society of Pediatric Oncology Europe
Neuroblastoma Group (SIOPEN) and Children’s Oncology
Group (COG) [3]. An increasing number of prognostically
significant genetic features, other than the well-known
MYCN amplification, have been recently studied and
sometimes included in developed clinical trials, in particular
for relapsed/refractory disease [4]. The available therapies
for treating NB are various but unfortunately not always
enough effective, especially for high-risk NB. Treatment of
high-risk NB remains the challenge with 5-years overall
survival (OS) not yet reaching 50% related to high risk of
relapse (80%) in the first 2 years from diagnosis [5]. Che-
motherapy, radiotherapy, surgical resection, myeloablative
therapy, and a maintenance therapy based on administration
of oral retinoids, are used alone or in combination according
to the specific localization and staging of the tumors.
Beta-adrenergic receptors (β-ARs) are G protein-coupled
receptors, responsible for mediating vasodilation, cardiac
functions, thermogenesis, and other numerous responses in
health tissues. However, it is now accepted that β-ARs
sustain also the pathogenesis of different cancers, from
benign tumors such as the infantile hemangioma [6, 7] to
several malignant tumor types including angiosarcoma [8],
breast cancer [9], ovarian cancer [10], and melanoma
[11, 12].
Until a few years ago, the β2-AR subtype was identified
as the most involved in tumor-related pathways [13].
However, an aberrant expression of the β3-AR subtype has
been recently shown in several cancers, such as leukemia,
vascular tumors, colon carcinoma [14–16], and many other
human cancers [17]. Moreover, recent studies have shown
that the use of selective β3-AR antagonists in melanoma
was effective in reducing tumor growth via direct anti-
tumoral effects [18] and by affecting tumor microenviron-
ment reactivity [19]. These results demonstrate that the β3-
AR is far more widespread in tumors than previously
thought, suggesting that it could play an important role in
cancer biology.
Interestingly, in in vivo and in vitro NB models, non-
selective β1-AR and β2-AR antagonists were able to affect
tumor growth alone or in combination with chemother-
apeutic agents [20, 21]. Nevertheless, whether the β3-AR
subtype is expressed in NB and whether it could play a role
in NB tumor biology has not been investigated so far.
Sphingosine 1-phosphate (S1P) is a powerful bioactive
lipid that affects a wide variety of cellular functions such as
proliferation, survival and differentiation. Many growth
factors, hormones and cytokines exploit sphingosine kinase
1 (SK1) and/or SK2, the enzymes that catalyze the ATP-
dependent production of S1P, to exert some of their bio-
logical effects that largely rely on binding to one or more of
the five specific G protein-coupled receptors (named
S1P1–5) [22]. There is an increasing number of literature
data showing the critical role played by S1P and its meta-
bolism in cancer [23]. While the role of SK1 in cancer has
been well characterized, the contribution of SK2 has
emerged only in the latest years. In fact, besides others
in vitro studies, in vivo data have reported that targeting
SK2 significantly reduces tumor growth in a range of
human xenograft models in mice [24–26]. SK2 expression
is elevated in NB cells and tissues; moreover, it has been
shown that S1P, by the specific engagement of S1P2,
induces VEGF expression, the main mediator of angio-
genesis, known to be associated with NB tumor progression
[27].
Our results clearly demonstrate that β3-AR is expressed
in NB tumors and that its modulation strongly affects tumor
growth. Moreover, we provide experimental evidence that
SK2/S1P2 axis is responsible for β3-AR-dependent effects
in NB and provide the molecular rationale to consider β3-
AR/SK2/S1P2 as a promising therapeutic target for NB
treatment.
Results
β3-AR is expressed in NB tumor cells
Despite the recent findings showing that β3-AR is exten-
sively expressed in several cancer tissues [17], the presence
of this receptor in NB has not yet been investigated. To
assess the expression of the β3-AR, and whether it is
modulated by an hypoxic environment, we cultured three
different NB cell lines, one murine (Neuro-2A) and two
human (SK-N-BE(2), BE(2)C), under normoxia (21% O2)
and hypoxia (1% O2) conditions for 24 h. Western blot
(WB) analysis showed that β3-AR protein was expressed in
all investigated NB cell lines, and that only in Neuro-2A
cells, β3-AR expression was significantly increased by
hypoxia (Fig. 1a). The β3-AR was found expressed also in
numerous cells derived from human NB patients, as shown
by immunofluorescence analysis of tumor sections (Fig.
1b). The staining procedure was validated by immuno-
fluorescence of positive control human bronchial epithe-
lium, previously reported to express β3-AR [28], and
negative control human epidermis (Supplementary Fig. 1).
The ability of several β1- and β2-blockers to exert an anti-
tumor activity in NB cells has been already demonstrated
[20, 21], however, the possible role played by the β3-AR in
maintaining NB survival is completely unknown. To assess
the effect of the β3-AR selective antagonist SR59230A on
cell survival, MTT assay was employed using different
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concentrations of SR59230A for 24 h in the three NB cell
lines. Results showed that the β3-AR antagonist was able to
reduce cell viability in a dose-dependent manner (Fig. 1c),
with significant effect at a concentration limit over 1 µM for
Neuro-2A cells and 5 µM for SK-N-BE(2) and BE(2)C).
These results suggest that the β3-AR is constitutively
expressed in NB cancer cells and that it might play a crucial
role in maintaining cell survival. In order to estimate off-
target toxicity of SR59230A, we performed a dose-
dependent cell survival MTT assay by using β3-AR
antagonist in human microvascular endothelium cells
HMEC-1 and human fibroblasts, IMR-90. In the above-
mentioned non-tumor cell types SR59230A was not toxic at
doses below 5 μM, as shown in Supplementary Fig. 2,
whereas concentrations starting from 5 μM decreased cell
survival in dose-dependent manner, even if at a lesser extent
compared to what observed in tumor cell lines (Fig. 1c).
β3-AR blockade modulates S1P metabolism and
signaling in human NB BE(2)C cells
Literature data showed that S1P signaling strongly affects
NB progression [27, 29]. Notably, a recent paper reported a
cross talk between the β3-AR and the S1P signaling in heart
failure [30]. In view of this experimental data, we wondered
whether these two pathways were potentially related in NB
tumor biology. To address our hypothesis, we performed
in vitro experiments in human BE(2)C cell line. This cell
line, defined as I-type NB cells, are one of the most
tumorigenic human NB cells with features of malignant
Fig. 1 β3-AR is constitutively
expressed in murine and human
neuroblastoma cells and it is
involved in cell survival. a WB
and relative densitometric
quantification analysis, showing
expression of β3-AR protein in
murine (Neuro-2A) and human
(BE(2)C, SK-N-BE(2)) NB cell
lines in normoxic (N) and
hypoxic condition (H). Results
were normalized to the
expression of β-actin and
reported as mean ± SD, fold
change over controls (normoxic
condition), set as 1. Blots are
representative of three
independent experiments.
Significance was calculated by
Unpaired t-test analysis with
equal SD (*P < 0.05).
b Immunofluorescence staining
of β3-AR on tumor sections of
two NBs (NB1, NB2) derived
from human patients, showing
numerous β3-AR positive cells.
Images are representative of
similar results obtained for n=
6. c MTT survival assay in
Neuro-2A, BE(2)C and SK-N-
BE(2) NB cell lines, treated with
different concentration of
SR59230A for 24 h. Results are
reported as mean ± SD of three
independent experiments
performed in triplicate.
Significance was calculated by
one-way ANOVA analysis
followed by Bonferroni’s post
hoc test (ns= not significant,
*P < 0.05, **P < 0.01,
****P < 0.0001)
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neural crest stem cells, such as high self-renewal and multi-
potency properties [31, 32]. Real time-PCR on BE(2)C cells
treated with sublethal dose of SR59230A (1 μM) for 24 h,
showed that, among the enzymes (SK1, SK2) receptors
(S1P1, S1P2, S1P3) and S1P transporter Spinster homolog 2
(Spns2) expressed in these cells, only the S1P2 receptor
transcript was downregulated when the β3-AR was antag-
onized (Fig. 2a). Nevertheless, WB analysis demonstrated
Fig. 2 β3-AR blockade modulates S1P signaling in human neuro-
blastoma BE(2)C cells. a RT-PCR of human NB BE(2)C cell line
treated with 1 μM SR59230A for 24 h. Change of mRNA expression
levels of receptors (S1P1, S1P2, S1P3), metabolic enzymes (SK1, SK2,
SPL) and transporter (Spns2) of S1P are reported as mean ± SD of
three independent experiments performed in triplicate, using the
2^(-ΔΔCt) method as described in Methods section. Data were nor-
malized to β-actin RNA expression and values of treated samples
reported as fold change over control, set as 1. Significance was cal-
culated by Unpaired t-test analysis with equal SD (**P < 0.01). b WB
and relative densitometric quantification analysis, showing protein
expression levels of SK1, SK2, and S1P2 in NB BE(2)C cell line after
24 h of 1 μM SR59230A treatment. Results were normalized to the
expression of β-actin and reported as mean ± SD, fold change over
control, set as 1. Blots are representative of three independent
experiments. Significance was calculated by Unpaired t-test analysis
with equal SD (*P < 0.05, ***P < 0.001). c WB and relative densito-
metric quantification analysis, showing protein expression levels of
β2-AR, β3-AR, SK2 and S1P2 in NB BE(2)C cell line after molecular
silencing of β2- and β3-AR. Results were normalized to the expression
of β-actin and reported as mean ± SD, fold change over control, set as
1. Blots are representative of three independent experiments. Sig-
nificance was calculated by one-way ANOVA analysis followed by
Bonferroni’s post hoc test (ns = not significant, *P < 0.05, **P < 0.01,
****P < 0.0001)
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that, protein levels of both S1P2 and SK2, were strongly
reduced in BE(2)C cells treated with SR59230A for 24 h,
while SK1 expression was not affected (Fig. 2b). To corro-
borate the pharmacological use of SR59230A as selective
antagonist of β3-AR in our model, we exploited an RNA
interference approach to down-regulate β2- and β3-ARs
using specific siRNAs of each receptor. As shown in Fig. 2c,
specific silencing of β3-AR decreased S1P2 and SK2, con-
firming the results obtained employing the β3-AR antagonist.
The reduction of S1P2 and SK2 protein levels was not
observed when β2-AR was downregulated, suggesting that
the modulation of S1P2 and SK2 exerted by SR59230A was
due to a selective β3-AR-antagonism. In addition, the
selective β3-AR agonist BRL37344 significantly increased
the expression of SK2 and S1P2 (Supplementary Fig. 3).
Taken together, these results suggest the existence of a
possible interplay between β3-AR and the S1P metabolism
and signaling in NB cells.
β3-AR blockade decreases cell proliferation and
increases neuronal differentiation of human NB BE
(2)C cells through the involvement of the S1P2
receptor
Among others, a current therapy for treating NB cancer
utilizes differentiating agents, such as retinoids [33, 34]. In
melanoma cells, β3-AR has been associated with main-
tenance of stemness potential [19] but the molecular
mechanisms responsible for this effect are still unknown.
Here we investigated whether β3-AR modulation could
affect the stemness/differentiation state in NB malignancy.
Since the differentiation process is usually accompanied by
a proliferation decrease of committed cells, first we eval-
uated whether β3-AR modulation could affect the pro-
liferation of BE(2)C NB cells. A [3H]-thymidine
incorporation proliferation assay showed that β3-AR phar-
macologic blockade decreased the proliferation rate of BE
(2)C NB cells, conversely, the activation of β3-AR by using
the selective agonist BRL37344, elicited an increased pro-
liferation (Fig. 3). Moreover, the anti-mitogenic action of
1 µM SR59230A was abolished in presence of the S1P2
agonist, CYM5520; conversely, we observed that the
mitogenic action exerted by BRL37344 was reverted in
presence of the SK2 inhibitor ABC294640. In agreement
with the involvement of S1P2, the incubation with S1P2
antagonist, JTE013, significantly reduced BRL37344-
dependent mitogenic effect. On the contrary, cell pro-
liferation was not affected by selective β1-AR- (Atenolol)
and a β1/β2-AR- (Propranolol) antagonists (Fig. 3), ruling
out the possible involvement of β1/β2-AR in SR59230A-
dependent anti-proliferative action.
Treatment of BE(2)C cells for 72 h with 1 μM
SR59230A was able to induce neurite outgrowth (Fig. 4a).
Moreover, the neuronal differentiation marker protein
Map2 was upregulated at protein level after 24 h of
SR59230A treatment (Fig. 4b). To confirm that the
SR59230A pharmacologic induction of the neuronal dif-
ferentiation marker Map2 in NB BE(2)C cells was due to a
selective β3-AR-blockade, we performed the silencing of
β3-AR mRNA expression. Western blot analysis showed
that β3-AR down-regulation switched NB phenotype to
neuronal differentiation by increasing the neuronal marker
Map2, corroborating the pharmacological approach (Fig.
4c). To investigate the involvement of the S1P2 receptor in
the neuronal differentiation induced by the β3-AR-block-
ade, we used the S1P2 agonist CYM5520. Interestingly,
the upregulation of the differentiation marker Map2
observed after β3-AR-blockade was completely abrogated
by treatment with the S1P2 receptor agonist CYM5520
(Fig. 4d).
Immunofluorescence staining of Map2 in BE(2)C cells
treated with SR59230A, in the presence or absence of the
S1P2-agonist CYM5520, demonstrated that S1P2 is
involved in β3-AR downstream effects, since S1P2
engagement by the agonist reverted Map2 expression
induced by β3-AR blockade (Fig. 4e). In addition, the
expression of the late neuronal differentiation marker
Neurofilament is in line with previous results, being upre-
gulated when the β3-AR was blocked by SR59230A,
whereas it was completely abrogated in the presence of
CYM5520 (Fig. 4f).
Fig. 3 β3-AR regulates proliferation rate of human neuroblastoma BE
(2)C cells through the involvement of SK2/S1P2 signaling.
3H-thymidine Proliferation Assay (1 μCi/well) of BE(2)C cell line
treated with 1 μM SR59230A in presence or not of 10 μM CYM5520,
1 μM BRL37344 in presence or not of 1 μM ABC294640 and 1 μM
JTE013, 1 μM Atenolol and 1 μM Propranolol for 24 h. Results are
reported as mean ± SD of three independent experiments. Significance
was calculated by one-way ANOVA analysis followed by Bonferro-
ni’s post hoc test (**P < 0.01 SR vs. CTRL, ****P < 0.0001 BRL vs.
CTRL; ####P < 0.0001 SR+CYM vs. SR; §P < 0.05 BRL+JTE vs.
BRL; §§§§P < 0.0001 BRL+ABC vs. BRL)
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Our data demonstrate that in NB cancer, β3-AR
blockade leads to a switch from a proliferative to a neu-
ronal differentiation state, and that this effect is com-
pletely abolished when the S1P2 receptor is triggered by a
selective agonist. These results prove the existence of a
functional cross talk between β3-AR and S1P signaling in
regulating the proliferation/differentiation balance in NB
cells.
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β3-AR blockade reduces stemness in human NB BE
(2)C cells by modulating the SK2/S1P2 signaling axis
The existence of self-renewing multipotent tumor cells is
considered a reservoir of malignant progenitors that are
responsible for NB growth and lack of sensitivity to che-
motherapeutics [35, 36]. The above-described data on β3-
AR role in the differentiation of NB cells, prompted us to
investigate whether β3-AR modulation could alter stem cell
features in human BE(2)C cells. Neurosphere formation
assay was performed and data showed that β3-AR and S1P
signaling modulation strongly affected the ability of NB
cells to make neurospheres (Fig. 5a). In particular, when β3-
AR was blocked by SR59230A the number of neurospheres
from BE(2)C cells was significantly decreased, and together
with this parameter, neurospheres displayed a smaller dia-
meter, compared to the control condition. Moreover, the
administration of S1P2 agonist CYM5520 counteracted both
these effects brought about by β3-AR-antagonist. On the
other side, β3-AR agonist BRL37344 induced a significant
increase of stemness potential, quantified by measuring both
number and size of neurospheres, and this effect was
completely abrogated when the SK2 enzyme was blocked
by the selective inhibitor ABC294640 (Fig. 5a–c). Although
the expression of the stem cell marker CD133 by flow
cytometry analysis of neurospheres showed no appreciable
difference when β3-AR and S1P signaling were modulated,
the expression of the stem cell marker CD34 was down-
regulated in the presence of SR59230A, and interestingly,
this effect was reverted by CYM5520. Furthermore,
BRL37344 increased the CD34 expression in neurospheres,
but when SK2 activity was pharmacologically blocked by
ABC294640, the expression of the stem marker was similar
to the control condition (Fig. 5d), leading to the conclusion
that SK2 was involved in the potentiation of stemness
downstream of β3-AR in NB.
Taken together these results highlight the role of the
cross-talk between β3-AR and SK2/S1P2 signaling axis, in
controlling the balance between stemness/differentiation of
human NB BE(2)C cells.
β3-AR blockade by SR59230A reduces NB tumor
growth in A/J mice, through the involvement of SK2
and S1P2
In different NB cells, several non-selective β-AR antago-
nists showed reduction of tumor proliferation and viability
in vitro and tumor growth in vivo [20, 21]. Nevertheless, the
role played by the β3-AR in NB tumor growth has never
been investigated. Driven by our in vitro results, we
investigated whether the β3-AR antagonist SR59230A
could affect tumor growth in a mice syngeneic model of NB
cancer. For this purpose, we injected subcutaneously
Neuro-2A cells in A/J mice and when tumor mass were
palpable, at 6 days, mice were treated every day for 8 days
until the sacrifice. As shown in Fig. 6a, b, in mice treated
with SR59230A for 8 days, there was a strong reduction of
NB tumor growth compared to vehicle-treated mice. In line
with previous data obtained in vitro, the tumor growth
impairment observed in SR59230A-treated mice was
Fig. 4 β3-AR blockade increases neuronal differentiation of human
neuroblastoma BE(2)C cells through the involvement of SK2/S1P2
signaling. a Images showing neurite outgrowth (black arrows) and
relative quantification in SR59230A and control condition after 72 h of
treatment of BE(2)C cells. To quantify neurite outgrowth, images were
acquired from six randomly chosen fields in each well in triplicate for
condition, and neurite-bearing cells were counted. Results are reported
as mean ± SD of three independent experiments. Significance was
calculated by Unpaired t-test analysis with equal SD (****P < 0.0001).
b WB and relative densitometric quantification analysis, showing
protein levels of the differentiation marker Map2 in BE(2)C cell line
treated with 1 μM SR59230A for 48 h. Results were normalized to the
expression of β-actin and reported as mean ± SD, fold change over
control, set as 1. Blot is representative of three independent experi-
ments. Significance was calculated by Unpaired t-test analysis with
equal SD (**P < 0.01). c WB and relative densitometric quantification
analysis, showing protein levels of Map2 in BE(2)C cell line trans-
fected with Scrambled (Scr)- and β3-AR-siRNA for 48 h. Results were
normalized to the expression of β-actin and reported as mean ± SD,
fold change over control, set as 1. Blot is representative of three
independent experiments. Significance was calculated by Unpaired t-
test analysis with equal SD (**P < 0.01). d WB and relative densito-
metric quantification analysis, showing protein levels of the differ-
entiation marker Map2 in BE(2)C cell line treated with 1 μM
SR59230A for 48 h, in presence or not of 10 μM CYM5520. Results
were normalized to the expression of β-actin and reported as mean ±
SD, fold change over control, set as 1. Blot is representative of three
independent experiments. Significance was calculated by two-way
ANOVA analysis followed by Bonferroni’s post hoc test (*P < 0.05;
#P < 0.05 CYM+SR vs. SR). e Upper panel: Immunofluorescence
images of BE(2)C cells treated with 1 μM SR59230A for 48 h, in
presence or not of 10 μM CYM5520 and stained with anti-Map2
antibody, Alexa-fluor488 secondary antibodies and propidium iodide
(PI). Images are representative of three independent experiments with
similar results. Scale bar 25 µm. Lower panel: Quantification of Map2-
associated fluorescence intensity normalized to PI, fold change above
control set as 1. Data are mean ± SD of six fields of each specimen
quantified in three independent experiments. SR59230A increases
Map2 in a statistically significant manner by one-way ANOVA (*P <
0.05); the pharmacological activation of S1P2 by CYM5520 abolishes
SR59230A-induced increase of Map2 in a statistically significant
manner by two-way ANOVA followed by Bonferroni's post hoc test
#P < 0.05. f Upper panel: Immunofluorescence images of BE(2)C cells
treated with 1 μM SR59230A for 72 h, in presence or not of 10 μM
CYM5520 and stained with anti-Neurofilament antibody, Alexa-
fluor488 secondary antibodies and PI. Images are representative of
three independent experiments with similar results. Scale bar 25 µm.
Lower panel: Quantification of Neurofilament-associated fluorescence
intensity normalized to PI, fold change above control set as 1. Data are
reported as mean ± SD as described above in section e. SR59230A
increases Neurofilament in a statistically significant manner by one-
way ANOVA (***P < 0.001); the pharmacological activation of S1P2
by CYM5520 abolishes SR59230A-induced increase of Neurofilament
in a statistically significant way by two-way ANOVA followed by
Bonferroni's post hoc test (###P < 0.001)
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partially reverted by the use of the S1P2-agonist CYM5520.
Intriguingly, a partial reduction of tumor growth was
observed in CYM5520 alone-treated mice that could be
explained by an anti-angiogenic action of S1P2 receptor as
shown in Supplementary Fig. 4. Interestingly, in mice
treated with the SK2 inhibitor ABC294640, tumor growth
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suppression was similar to that observed in SR-treated mice.
Moreover, there was no further decrease in tumor size in
mice co-treated with the β3-AR antagonist together with
SK2 inhibitor, compared to β3-AR antagonist alone.
Finally, tumor weight after 8 days of treatments, showed a
strong reduction when mice where treated with the β3-AR-
antagonist SR59230A. Again, as for the tumor growth rate,
this effect was significantly reverted by the S1P2-agonist
CYM5520, and on the other hand, there was no significant
difference when mice where treated with both SR59230A
and ABC294640 compared to SR59230A alone (Fig. 6c).
The quantification of epinephrine and norepinephrine in
plasma of A/J mice treated with SR59230A and
ABC294640, in Supplementary Fig. 5a, b, clearly indicated
that in our model both SK2 inhibition and β3-AR antag-
onism were able to decrease plasmatic concentration of
norepinephrine, whereas ABC294640 significantly
decreased epinephrine amount as well. Moreover, as shown
in Fig. 6d, both SR59230A and ABC294640 strongly
decreased S1P levels in the tumor mass.
The in vivo results clearly support the involvement of the
β3-AR in sustaining the NB tumor progression. Moreover,
the specific role played by the β3-AR in NB relies, at least
in part, on the S1P signaling pathway via SK2 and S1P2
modulation.
NB tumor growth reduction exerted by SR59230A
via modulation of SK2/S1P2 signaling axis, is
associated to increased neuronal differentiation of
NB cells
With the specific purpose to analyze the differentiation state
in the tumor mass isolated from syngeneic mice treated with
β3/SK2/S1P2 modulators, we performed WB and IF ana-
lyses to study the expression of early, intermediate and late
neuronal markers. As shown in Fig. 7a, the β3-AR-
antagonist SR59230A and the SK2-inhibitor ABC294640,
were both able to decrease the protein expression levels of
the early neuronal differentiation marker NeuroD1 in tumor
mass excised from A/J syngeneic mice; however, in the
presence of the S1P2-agonist CYM5520, this effect was
abrogated. On the contrary, the expression levels of the
intermediate neuronal differentiation marker Map2 and of
the late differentiation marker Neurofilament, were upre-
gulated in SR59230A- or ABC294640-treated mice. Strik-
ingly, the expression of these differentiation markers in
mice administered with SR59230A in presence of the S1P2
agonist CYM5520, were comparable to the vehicle condi-
tion (Fig. 7b, c).
The data obtained in vivo corroborate our preliminary
results, and highlight the crucial role played by the β3-AR
in controlling the tumor growth and the differentiation grade
of NB tumor. Moreover, we confirm that the biological
effects observed in β3-AR-blockade conditions rely on the
modulation of the S1P signaling pathway.
Discussion
The effects of nonselective β-blocker propranolol in com-
bination with anti-cancer agents has been already reported
in different oncologic diseases including NB [21], whereas
the specific involvement of β3-AR was not investigated.
Recently, β3-AR expression was analyzed in several cancer
tissues. Among different tumor specimens, higher levels of
β3-AR were detected in melanoma and moderate levels of
expression were observed across cancer tissues such as
thyroid papillary carcinoma and T-cell lymphoma [17].
Literature data have already shown that β3-AR, which
expression increases under hypoxic conditions, is involved
in melanoma growth, since its blockade reduced tumor
growth in vivo [18]. Moreover, β3-AR activation sustained
melanoma growth and aggressiveness by driving stromal
microenvironment towards the secretion of angiogenetic
and pro-inflammatory cytokines [19], thus involving β3-AR
in adaptive responses of melanoma. However, the expres-
sion and possible dysregulation of β3-AR have not yet been
investigated in NB. Here we show for the first time that β3-
AR is constitutively expressed in NB cells, whereas β3-AR
Fig. 5 β3-AR blockade reduces stemness in human neuroblastoma BE
(2)C cells by modulating the SK2/S1P2 signaling axis. Neurospheres
formation assay of human neuroblastoma BE(2)C cell line. Cells were
plated in MW24 (1 × 104 cells/well) with Neurosphere basic medium
(see “Methods” section) and after 24 h treated with 1 μM SR59230A or
1 μM BRL37344, in presence or not of 10 μM CYM5520 or 1 μM
ABC294640. Once formed, spheres were disrupted and cells re-plated
for a second passage (P2). a Images were taken after 7 days of neu-
rosphere formation (P2). The effect of the treatments on stemness
features of BE(2)C neurospheres, was evaluated by using different
assays. b Number of neurospheres formed per well was counted using
an optical microscope and compared to the control condition. Results
are reported as mean ± SD and are representative of three independent
experiments. Significance was calculated by Unpaired t-test analysis
with equal SD (**P < 0.01, ***P < 0.001) and two-way ANOVA
analysis followed by Bonferroni’s post hoc test (§§§P < 0.001 ABC
+BRL vs. BRL). c Average diameter of the spheres was quantified by
using the ImageJ Software. Results are reported as mean ± SD and are
representative of three independent experiments. Significance was
calculated by Unpaired t-test analysis with equal SD (**P < 0.01,
***P < 0.001) and two-way ANOVA analysis followed by Bonferro-
ni’s post hoc test (#P < 0.05 CYM+SR vs. SR; §§§P < 0.001 ABC
+BRL vs. BRL). d Flow cytometry analysis of neurospheres was
performed by using MACSQuant Analyzer 10 (Miltenyi Biotech).
After disruption of the spheres, cells were stained with anti-CD34-PE-
Vio770, anti-CD133-APC antibodies and Viobility Fixable dyes.
Results were reported as mean ± SD of CD34 positive cells and are
representative of three independent experiments. Significance was
calculated by Unpaired t-test analysis with equal SD (**P < 0.01,
***P < 0.001) and two-way ANOVA analysis followed by Bonferro-
ni’s post hoc test (###P < 0.001 CYM+SR vs. SR; §§P < 0.01 ABC
+BRL vs. BRL)
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is reported to be induced under hypoxia in melanoma cells
[18]. In this study, three different NB cell lines have been
employed, murine Neuro-2A for the in vivo syngeneic
model and human SK-N-BE(2) and BE(2)C for the in vitro
experiments, showing for the first time that β3-AR is con-
stitutively expressed in all the above-mentioned NB cells.
Fig. 6 β3-AR blockade reduces tumor growth in A/J mice through the
involvement of SK2/S1P2 signaling axis. Neuro-2A cells were injected
subcutaneously (1 × 106 cells) in the flank of A/J female mice. When a
palpable tumor mass was formed (6 days), mice were treated with
Vehicle (i.p.), SR59230A 10 mg/kg (i.p.) alone or in combination with
CYM5520 5 mg/kg (i.p.) and ABC294640 30 mg/kg (p.o.). a After
8 days of treatment, mice were sacrificed and tumor mass excised;
images of tumors are representative of the final size of all tumors
respectively for each treatment (n= 6 for group). b Tumor growth rate
obtained by measuring tumor size of the mass calculated as Volume=
[(length × widht)2/2] in Vehicle (n= 6), SR59230A (n= 6),
CYM5520 (n= 6) and SR59230A+CYM5520 (n= 6) (top) and
Vehicle (n= 6), SR59230A (n= 6), ABC294640 (n= 6) and
SR59230A+ABC294640 (n= 6) (bottom). Vehicle and SR tumor size
results reported in (top) and (bottom) graphs are referred to the same
tumors. Significance was calculated by two-way ANOVA analysis
followed by Bonferroni’s post hoc test (*P < 0.05, **P < 0.01,
****P < 0.0001; ##P < 0.01 SR+CYM vs. SR, ####P < 0.0001 SR
+CYM vs. SR; §§§P < 0.001, §§§§P < 0.0001 Vehicle vs. ABC). c
Tumor weight at the end point of the experiment (14 days) (n= 6 per
group). Results are reported as individual dots with mean (central line)
±SD. Significance was calculated by two-way ANOVA analysis fol-
lowed by Bonferroni’s post hoc test (****P < 0.0001; ##P < 0.01 SR
+CYM vs. SR; §§§§P < 0.0001 ABC vs. Vehicle). d S1P measurement
in tumors of Vehicle- (n= 3), SR59230A- (n= 3) and ABC294640-
treated mice (n= 3). Results are reported as mean ± SD. Significance
was calculated by one-way ANOVA analysis followed by Bonferro-
ni’s post hoc test (**P < 0.01, ***P < 0.001)
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Noteworthy, higher levels of catecholamine metabolites that
characterize NB tumor condition reflect catecholamine
production by tumor microenvironment. We can speculate
that catecholamines may target cancer cells through the
activation of β3-AR, contributing to a feedforward loop of
growth and malignancy in NB cancer. Indeed, the decrease
of catecholamine levels in plasma from NB mice after β3-
AR blockade or SK2 inhibition reinforces our mechanistic
model of S1P/β3-AR crosstalk in NB (Supplementary
Fig. 5).
We focused our attention to effects elicited by a sublethal
dose of β3-AR antagonist SR59230A (1 µM), since its
moderate toxicity at concentrations over 5 µM might be
partially ascribed to its off-target effect, as we show in non-
tumor cell lines such as human fibroblast and endothelial
cells (Supplementary Fig. 2). The effects of 1 µM
SR59230A treatment as a pharmacological tool to block β3-
AR phenocopy those obtained by RNA interference
approach, thus confirming in our model the specificity and
selectivity of SR59230A for subsequent experiments.
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A strong relationship between cellular differentiation and
tumorigenesis in NB has come from the Shimada histology-
grading system, in which the differentiation grade has an
important prognostic significance, being the undiffer-
entiated tumors the most malignant [37]. Besides reducing
tumor cell viability, pharmacological tools that hit the stem
cell potential and push cells towards differentiation, thus
counteracting the onset of chemoresistance, may represent a
promising approach to treat NB. In fact, high-risk cases of
NB face poor prognosis due to therapy-resistant relapse that
relies on the presence of cancer stem cells, characterized by
a poorly differentiated phenotype. For this reason, high-risk
NB is currently treated with the differentiating agent reti-
noic acid at completion of cytotoxic therapy. Although this
improves survival, in metastatic NB patients the time-free
survival rate still remains quite low [38]. Therefore, we
focused our attention on neuronal differentiation and per-
formed subsequent experiment by using sublethal doses of
SR59230A, dissecting a crucial role for β3-AR in the bal-
ance between stemness and differentiation of NB cells.
Intriguingly, the analysis of neuronal differentiation of BE
(2)C cells by morphological and molecular approaches
demonstrated that β3-AR blockade is capable to increase
neurite formation and neuronal markers expression. The
decreased protein expression of the early neuronal
differentiation marker NeuroD1 in NB tumors excised from
SR59230A-treated mice, strengthens our in vitro results on
the role of the β3-AR in NB biology, being high levels of
this marker involved in the promotion of NB progression.
Interestingly, NeuroD1 has been also involved in the
induction of anaplastic lymphoma kinase (ALK), known to
be one of the most important predisposition genes for NB
[39] tumorigenesis, thus, hinting that NeuroD1 down-
regulation in SR59230A-treated tumors could counteract
ALK in sustaining the NB tumorigenesis.
Despite the CD133 antigen has been recognized as one
of the most important stemness-related markers in NB
[40, 41], we observe that neurospheres from BE(2)C cells
show a slight expression of the CD133 antigen, and no
significant changed expression of this marker following β3-
AR modulation. Instead, the expression of the CD34 anti-
gen is significantly affected by the binding of β3-AR and
modulation of S1P signaling. These results are in agreement
with literature data, in fact, despite the CD34 antigen was
firstly identified as a hematopoietic marker, several studies
demonstrated that it represents a specific marker for cancer
stem cells in NB. Moreover, NB cells and spheres derived
from the bone marrow metastasis of high-risk tumors, as
well as our spheres from BE(2)C cell line, do not express
appreciable levels of CD133, instead contain CD34 enri-
ched subpopulation, identified as the most tumorigenic cells
and responsible for relapse in NB patients [42–45]. Our
results therefore reinforce the crucial role played by the β3-
AR in controlling the stemness features of tumorigenic
subpopulations of cells in NB cancer. Therefore, it can be
assumed that catecholamine, besides being released to
promote NB growth, modulate the balance between differ-
entiation and stemness of NB cells via β3-AR activation.
Evidence for β3-AR/S1P cross-talk have been recently
reported and this molecular interplay seems to be involved
in physiopathological effects in different cellular contexts
[30, 46]. The occurrence of functional interplay between β3-
AR and SK/S1P axis has been demonstrated by both
pharmacological and RNA interference approach, and these
results were further confirmed by the employment of a
specific β3-AR agonist. In our NB cell model, β3-AR
antagonist potently down-regulates SK2 and S1P2 whereas
it does not affect SK1 expression. Conversely, the treatment
with BRL37344 inversely affects the expression of SK2 and
S1P2. We can speculate that an appreciable basal con-
stitutive activity of the β3-AR occurs in NB cells, even
though the binding of β3-AR agonist further potentiates
receptor activation.
Noteworthy, our results are in agreement with published
studies reporting that SK2 is highly expressed in NB, being
required for the production of bioactive lipid S1P that via
S1P2 exerts biological function in NB [27]. Moreover, the
sphingosine analogue and pro-drug FTY720 decreases SK2
Fig. 7 Neuroblastoma tumor growth reduction exerted by SR59230A
via SK2/S1P2 signaling axis is accompanied with an increased neu-
ronal differentiation of NB cells. a WB and relative densitometric
quantification analysis, showing the protein expression levels of the
early differentiation marker NeuroD1. Lysates were obtained from
tumor mass (at 14 days) of Vehicle-, SR59230A-, CYM5520- and
SR59230A+CYM5520-treated mice (n= 3 for each group) (top) and
Vehicle-, SR59230A-, ABC294640- and SR59230A+ABC294640-
treated mice (n= 3 for each group) (bottom). Significance was cal-
culated by two-way ANOVA analysis followed by Bonferroni’s post
hoc test (*P < 0.05, **P < 0.01; #P < 0.05 SR+CYM vs. SR). b Upper
panel: Immunofluorescence of paraffin-embedded tumor sections
showing expression of the neuronal differentiation marker Map2.
Images are representative of similar results obtained for Vehicle-
(n= 5), SR59230A- (n= 5), CYM5520- (n= 5), SR59230A
+CYM5520- (n= 5), ABC294640- (n= 5) and SR59230A
+ABC294640-treated mice (n= 5). Lower panel: Quantification of
Map2-associated fluorescence intensity. Data are mean ± SD of eight
fields of each specimen quantified in three independent experiments.
Significance was calculated by one-way ANOVA analysis followed by
Bonferroni’s post hoc test (****P < 0.0001 SR vs. Vehicle, ***P <
0.0001 ABC vs. Vehicle, ****P < 0.0001 SR+ABC vs. Vehicle;
####P < 0.0001 SR+CYM vs. SR. c Upper panel: Immunofluorescence
of paraffin-embedded tumor sections showing expression of the neu-
ronal differentiation marker Neurofilament. Images are representative
of similar results obtained for Vehicle- (n= 5), SR59230A- (n= 5),
CYM5520- (n= 5), SR59230A+CYM5520- (n= 5), ABC294640- (n
= 5) and SR59230A+ABC294640-treated mice (n= 5). Lower panel:
Quantification of Neurofilament-associated fluorescence intensity.
Data are mean ± SD of eight fields of each specimen quantified in three
independent experiments. Significance was calculated by one-way
ANOVA analysis followed by Bonferroni’s post hoc test (****P <
0.0001 SR vs. Vehicle, ***P < 0.0001 ABC vs. Vehicle, ****P <
0.0001 SR+ABC vs. Vehicle; ####P < 0.0001 SR+CYM vs. SR
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activation and cellular proliferation of NB in vitro and
tumor growth in vivo showing a synergistic effect with
topotecan [29].
These results reinforce the notion that SK/S1PR axis is a
signaling pathway that can be exploited by different exo-
genous cues to promote tumor growth and aggressiveness.
In particular, the specific cross talk with β3-AR is funda-
mental for the induction of neuronal differentiation in NB
that could be an innovative and efficacious strategy to treat
high-risk NB patients. The observation that
CYM5520 slightly decreases NB growth in mice can be
explained by the negative role of S1P2 in tumor angiogen-
esis (Supplementary Fig. 4), that possibly affects tumor
growth in vivo, in agreement with literature data [47]. It is
worth to mention that S1P2 is widely distributed in tissues
and exerts systemic effects that could be difficult to dissect.
Anyway, these effects are only apparently in contrast with
our mechanistic model, since in the presence of CYM5520
the effect of SR59230A was completely reverted both
in vitro and in vivo. We hypothesize that the transactivation
of S1P2 by β3-AR occurs via the well-known S1P inside-
out signaling, that requires the involvement of SK2 acti-
vation and S1P release. Indeed, both β3-AR blockade and
SK2 inhibition significantly decrease S1P levels in the
tumor mass. Although we cannot exclude a partial com-
pensation effect of SK1 after inhibition of SK2 at the level
of systemic S1P, whether this occurs it does not revert S1P
drop by ABC294640 treatment in tumors.
In summary, our findings highlight the crucial role
played by the β3-AR in regulating tumorigenesis of NB.
Intensive research aimed at addressing the molecular
mechanisms of β3-AR and SK/S1P axis will feasibly
identify innovative targets to treat high-risk NB. These
findings may have relevant implications for therapeutic
purposes, since the available therapies are still not effective
enough for metastatic diseases. Furthermore, biologically
based treatments that specifically target pathways respon-
sible for malignant transformation and progression in NB




SK-N-BE(2), BE(2)C human NB cancer cells, and Neuro-
2A murine NB cancer cells were obtained from ATCC. SK-
N-BE(2) and BE(2)C cells were grown in DMEM:
F12 supplemented with 10% of FBS, Neuro-2A cells were
grown in DMEM supplemented with 10% of FBS. Cell
lines were cultured at 37 °C water-satured, 5% CO2 atmo-
sphere, and 21% O2 for normoxia, and 1% O2 for hypoxia.
Western blot analysis
Cells were collected and lysed in RIPA buffer containing
protease inhibitor cocktail. After quantification, 20 μg of
total proteins were used to perform an SDS-PAGE and WB
analysis. PVDF membranes were incubated overnight with
the primary antibodies (anti-Map2, Cell Signaling, #4542;
anti-SK1 and anti-SK2, ECM Biosciences, #SP1621 and
#SP4621, respectively; anti-S1P2, Proteintech, 21180-1-AP;
anti-NeuroD1, Abcam, ab60704; anti-β2-AR sc-9042, anti-
β3-AR sc-13108 and anti-β-actin sc-1615, Santa Cruz
Biotechnology) at 4 °C and then with specific secondary
antibodies for 1 h at room temperature. Binding of the
antibodies with the specific proteins has been detected by
using Clarity Western ECL Substrate (Biorad).
MTT assay
Viability of tumor cells was evaluated using an MTT assay.
NB cells were treated for 24 h with different concentration
of SR59230A and then maintained in MTT for 1 h at 37 °C
before lysis with an equal volume of DMSO. The absor-
bance of the solubilized dye was evaluated at 570 nm using
a spectrophotometer.
Real-time PCR
Gene expression analysis was performed using 2^(-ΔΔCT)
comparative method of quantification [48]. Briefly, total RNA
(1 µg), extracted with TriReagent™ (Sigma-Aldrich S.r.l.)
was reverse transcribed using iScript™ cDNA Synthesis Kit
for RT-qPCR (Bio-Rad Laboratories S.r.l.) according to the
manufacturer's instructions. The quantification of target gene
mRNA levels was performed in triplicate for each specimen
employing TaqMan Universal Master Mix and the automated
ABI Prism 7500 Sequence Detector System (Thermo Fisher
Scientific INC). Human specific TaqMan Gene Expression
Assays employed for gene expression studies were purchased
from Thermo Fisher Scientific INC. Simultaneous amplifica-
tion of the target sequences (SPHK1:Hs00184211_m1,
SPHK2:Hs01016543_g1, SGPL1:Hs00393705_m1, SPNS2:
Hs01390449_g1, S1PR1:Hs00173499_m1, S1PR2:Hs01003
373_m1, S1PR3:Hs01019574_m1 Gene Expression assays)
together with the housekeeping gene, β-actin (ACTB:
Hs99999903_m1 Gene Expression assay) was carried out
essentially as previously described [49]. Results were ana-
lyzed by ABI Prism Sequence Detection Systems software,
version 1.7 (Thermo Fisher Scientific INC).
Cell transfection
Cells grown into tissue culture 6-well plates, and when were
60% confluent were transfected with siRNA duplexes
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(SASI_Hs01_00015585 and SASI_Hs01_00015586 for β3-
AR; SASI_Hs01_00209061 and SASI_Hs01_00209062 for
β2-AR) using Lipofectamine RNAiMAX (Thermo Fisher
Scientific INC), according to the manufacturer's instructions
as previously described [50]. Briefly, Lipofectamine
RNAiMAX was incubated with siRNA in DMEM without
serum and antibiotics for 20 min, and afterward the lipid/
RNA complexes were added to cells to a final concentration
of 20 nM in DMEM containing serum. After 24 h, cells
were shifted to DMEM without serum and then used for the
experiments within 72 h from the beginning of transfection.
Proliferation assay
Cell proliferation was determined by measuring [3H]-thy-
midine incorporation. BE(2)C cells were serum-starved for
24 h and then challenged with different molecules as
described in the figure legend. [3H]-thymidine (0.5 μCi/
well) was added for the last 4 h of incubation. Cells were
washed in ice-cold PBS before 500 μl addition of 10% tri-
chloroacetic acid (TCA) for 5 min at 4 °C. TCA was
removed and 250 μl of ethanol:ether (3:1 v/v) solution was
added; plates were then collocated under chemical hood
until complete evaporation of the solution. Samples were
then lysed in 0.25 N NaOH for 2 h at 37 °C. Incorporation
of [3H]-thymidine was measured by scintillation counting.
Immunofluorescence of cells and tissues
Immunofluorescence analysis of human and murine tumor
mass was performed as follows. Samples were rapidly
excised, fixed in buffered 4% formaldehyde for 24 h and
paraffin-embedded. Histological sections, 5 µm thick, were
cut from samples, were deparaffinised and boiled for 10 min
in sodium citrate buffer (10 mM, pH 6.0; Bio-Optica) for
antigen retrieval and immunostained over night at 4 °C with
rabbit polyclonal anti-Neurofilament antibody (1:100, anti-
160kD Neurofilament medium, Abcam, ab64300) and rab-
bit polyclonal anti-MAP2 antibody (1:50; anti-Map2, Cell
Signaling, #4542) for murine tumors, and rabbit polyclonal
anti-β3 receptor antibody (1:50, Abcam, ab140713) for
human NB. Immune reaction was revealed incubating the
section with donkey anti-rabbit Alexa Fluor 594-conjugated
IgG (1:350; Jackson Laboratory). After counterstaining
with 4,6-diamidino-2-phenylindole (DAPI), representative
images were acquired by an Olympus BX63 microscope
coupled to CellSens Dimension Imaging Software version
1.6 (Olympus).
Immunofluorescence analysis of BE(2)C cells was per-
formed as follows. BE(2)C were seeded on microscope
slides poly-lysine coated (35,000 cells/well in Nunc Lab-
Tek chamber slide 4) and at 60–70% confluence were
serum-starved, then pre-incubated with pharmacological
drugs 30 min before being challenged with 1 μM
SR59230A at 37 °C. Immunofluorescence analysis was
performed essentially as previously described [50]. Briefly,
after different time intervals indicated in legends, cells were
fixed in 2% paraformaldehyde in PBS for 20 min. Per-
meabilization and quenching were obtained by adding a
solution containing Triton X-100 0.1% and ethanolamine
(1: 165) for 30 min at room temperature. Cells were then
blocked in 1% BSA for 1 h and incubated with primary
antibodies (anti-160kD Neurofilament medium, Abcam,
ab64300; anti-Map2, Cell Signaling, #4542) for 1 h and
subsequently, after repeated washes in PBS, slides were
incubated with Alexa-fluor488 secondary antibodies. Ima-
ges were obtained using a Leica SP8 laser scanning con-
focal microscope (Leica Microsystems GmbH, Wetzlar,
Germany) with a 63X objective.
Neurosphere assay
For neurosphere formation assay, 24-well plates were
coated with 1,2% of Poly(2-hydroxyethyl methacrylate)
diluted in 95% ethanol. Then, cells were plated (5.000/well)
in Neurosphere basic medium composed of DMEM:
F12 supplemented with 2% B27, 1% N2, 20 ng/ml FGF and
20 ng/ml EGF. After 24 h, cells were treated with 1 μM
SR59230A and 1 μM BRL37344 alone, or in combination
with 1 μM ABC294640 and 10 μM CYM5520. Once
formed, spheres were disrupted and cells re-plated for a
second passage (P2). After 7 days, neurosphere were
counted and the diameter size measured using the ImageJ
software (National Institutes of Health, U.S.). Neurosphere
were then disrupted and stained for a flow cytometry
analysis.
Flow cytometry analysis
To evaluate the expression of the antigens CD34 and
CD133, neurospheres of human NB BE(2)C cells (P2) were
mechanically dissociated, and single cells suspended in
staining buffer. Cells were than treated with FcR blocking
reagent and then stained with Viobility 488/520 Fixable
dye, anti-CD34(PE-Vio770) and anti-CD-133(APC) anti-
bodies (Miltenyi Biotec). After staining, cells were sub-
jected to flow cytometry by using a Miltenyi Biotec
MACSQuant Analyzer 10. Results were analyzed by using
FlowlogicTM Software.
S1P quantification
The S1P concentration in tumor mass was determined using
the Sphingosine 1-phosphate Assay Kit (Echelon Bios-
ciences, K-1900) according to the manufacturer’s instruc-
tions. The absorbance at 450 nm was measured, and the
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concentration of S1P in the samples was determined by
comparison with the standard curve.
Tumor syngeneic model
Female NCI A/JCr mice 4-weeks-old were bought from
Charles River Laboratories (Frederick). Neuro-2A cells
were subcutaneously implanted in A/J recipient mice by
injecting 1 × 106 cells in 100 µl of PBS in the right flank.
When Neuro-2A cells formed a palpable tumor (about
6 days), treatments started. The treatments were admini-
strated twice a day for SR59230A and Vehicle, and once a
day for ABC294640 and CYM5520. SR59230A (Tocris
Bioscence) was delivered at 10 mg/kg of physiological
solution via intraperitoneal (i.p.); ABC294640 (MedChem
Express) was delivered at 30 mg/kg in 0,375% of Poly-
sorbate 80 in PBS via per os (p.o); CYM5520 (Sigma
Aldrich) was delivered at 5 mg/kg in 3.6% DMSO in PBS
via i.p. Tumor growth rate was evaluated by measuring
tumor mass with a caliber, and tumor mass volume calcu-
lated as Volume= [(length × width)2/2]. Mice were sacri-
ficed after 8 days of treatment.
Statistics
Densitometric analysis of the WB bands was performed by
ImageJ software. Graphical representations were obtained by
GraphPad Prism 6.0 (GraphPad Software, San Diego, CA),
and statistical analyses were performed using Unpaired stu-
dent’s t-test, one-way and two-way ANOVA analysis of
variance followed by Bonferroni’s post hoc test. For MTT
survival assay significance was calculated by one-way
ANOVA analysis followed by Bonferroni’s post hoc test.
For Real Time-PCR significance was calculated by Unpaired
t-test analysis with equal SD. For [3H]-thymidine Proliferation
Assay significance was calculated by Unpaired t-test analysis
with equal SD. For the analysis of neurosphere significance
was calculated by Unpaired t-test analysis with equal SD and
two-way ANOVA analysis followed by Bonferroni’s post hoc
test. For tumor growth rate significance was calculated by
two-way ANOVA analysis followed by Bonferroni’s post hoc
test. For the analysis of tumors weight significance was cal-
culated by two-way ANOVA analysis followed by Bonfer-
roni’s post hoc test. Asterisks show statistical significance as
reported in figure legends.
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